Latest news articles

Added 9 hours ago Drug news

Lilly presents 52-week head-to-head (SPIRIT-H2H) data from Taltz v. Humira trial in psoriatic arthritis.

Eli Lilly and Company announced the 52-week results from the Phase IIIb/IV SPIRIT-Head-to-Head (H2H) study of Taltz (ixekizumab) versus Humira...

Added 1 day ago Drug news

Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in phase III TULIP 2 trial. - AstraZeneca

AstraZeneca will tomorrow present detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine...

Added 1 day ago Drug news

Phase III study of Tremfya meets endpoints in psoriatic arthritis.- Janssen Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced 24-week Phase III data showing a significantly greater proportion of patients...

Search all news articles for Dermatology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Psoriasis Academy

Psoriasis Academy

Learn about the burden of psoriasis, unmet needs, the tools used to assess severity and treatment response, what we know about the pathophysiology behind the condition and what the current guidelines say.

+ 1 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Load more

 

Guidelines

Diabetic foot problems: prevention and management

This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. The guideline aims to reduce variation in practice.

Added 4 years ago

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light–based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents...

Added 3 months ago

UrgoStart for treating diabetic foot ulcers and leg ulcers

UrgoStart is a type of interactive wound dressing. Clinical trial evidence shows that using UrgoStart to treat diabetic foot ulcers increases wound healing compared with non-interactive dressings.

Added 3 months ago

Search all guidelines for Dermatology
 

Journal articles

Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications.

Chronic urticaria (CU) is a mast cell-driven disease characterized by the development of wheals, angioedema, or both for more than 6 weeks. The two major sub-types are chronic spontaneous urticaria (CSU) and inducible urticaria.

Added 15 days ago

Ligelizumab for Chronic Spontaneous Urticaria.

Background: In the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control. Ligelizumab is a next-generation high-affinity humanized monoclonal...

Added 15 days ago

Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.

Introduction: Chronic spontaneous urticaria (CSU) affects approximately 1% of the population, affecting both children and adults. Omalizumab (Oma) is a therapeutic option for patients with refractory forms of CSU.

Added 15 days ago

Search all journal articles for Dermatology
 

Clinical trials

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Added 15 days ago

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Brief Summary:
This study will assess the safety and effIcacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Added 16 days ago

A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare)

The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.

Added 16 days ago

Search all clinical trials for Dermatology
 

Blog Posts

Lauren McCracken

EAACI hot topics: Hereditary angioedema (HAE)

Posted 1 year ago

For many the fear of the unknown is a daunting thought, but particularly so for patients with HAE. Left untreated, this disease causes unpredictable recurrent severe swelling, typically of the limbs, face, intestinal tract and airway.

Lisa Lishman

EULAR 2018 – Biosimilars: the future of rheumatology?

Posted 1 year ago

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

Lauren McCracken

EAACI hot topics: Allergen specific immunotherapy (AIT)

Posted 1 year ago

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.

CME

EAACI 2017: The future of urticaria – advances in CSU research

EAACI 2017: The future of urticaria – advances in CSU research
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics
Accrediting body
Credits available
0
Registration required
1
Subscription fee
FREE

Managing CSU and its comorbidities: from primary to secondary care

Managing CSU and its comorbidities: from primary to secondary care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Dermatology